Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Sepsis; shock/trauma

Cold-inducible RNA-binding protein (CIRP)

In vitro and rodent studies suggest decreasing CIRP levels could help treat hemorrhagic shock and sepsis. In hemorrhaged human patients and in a rat model of hemorrhagic shock, serum CIRP levels were greater than those in healthy controls. In mouse and rat models of hemorrhagic shock and sepsis, Cirp knockout or a Cirp-neutralizing antibody decreased the inflammatory response and mortality compared with no knockout or an IgG control. Next steps include testing therapeutic peptide fragments of human CIRP that interfere with its function in animal models of sepsis.

SciBX 6(43); doi:10.1038/scibx.2013.1235
Published online Nov. 7, 2013

Patent applications filed; TheraSource LLC has an option to license the IP; available for licensing from The Feinstein Institute for Medical Research and TheraSource

Qiang, X. et al. Nat. Med.; published online Oct. 6, 2013;
doi:10.1038/nm.3368
Contact: Ping Wang, The Feinstein Institute for Medical Research, Manhasset, N.Y.
e-mail:

pwang@nshs.edu